Astellas Seeks Mycamine Candidemia Claim With sNDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Antifungal facing additional competition this year following approval of Pfizer, Schering-Plough products.
You may also be interested in...
Astellas Wins Additional Indications For Antifungal Mycamine
Injectable for Candida infections gets FDA okay for candidemia, acute disseminated candidiasis, candida peritonitis and abscesses.
Astellas Wins Additional Indications For Antifungal Mycamine
Injectable for Candida infections gets FDA okay for candidemia, acute disseminated candidiasis, candida peritonitis and abscesses.
Noxafil Gains Additional Oropharyngeal Candidiasis Indication
Approval for Schering-Plough’s antifungal comes just one month after FDA cleared it for invasive Aspergillus and Candida infections.